Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2006

View Archived Issues

Roche and Amira sign research collaboration and licensing option agreements

Cellegesic to be reviewed by FDA Advisory Committee in April

Preclinical findings show Miraxion has neuroprotective effects in Parkinson's

Second phase I trial begins for third-generation taxane TPI-287

Series B financing to support pipeline development at Xytis

Hana demonstrates bioequivalence of Zensana ondansetron oral spray

TAP terminates sublicensing agreement with Santarus

IND submission for BEMA LA for moderate to severe pain

Enrollment open in phase IIb kidney transplant study of ISA-247

Phase I study for PV-903 for treatment of recurrent miscarriages

Ibuprofen may delay or prevent PD

MUC1 immunoassay may detect pancreatic cancer

Neurocrine updates FDA review of indiplon NDAs

Hemopure to be submitted for European approval in mid-2006

EntreMed completes Miikana acquisition

PR Pharmaceuticals and OSI collaborate on sustained-release Macugen

GlobeImmune closes Series B financing

European orphan drug designation for Amplimexon in ovarian cancer

MRE-0094 enters phase II for chronic neuropathic diabetic foot ulcers

Phase III program commences for Vanquix for acute, repetitive epileptic seizures

New analogue of celecoxib mimics antitumor activity in MM without COX-2 inhibition

Novel antiinfective agents disclosed in recent Johnson & Johnson patent

Vitragan MAA accepted for review

Recent patents report new therapeutic agents for diabetes and other endocrine-related disorders

Fast track designation for FavId in B-cell follicular NHL

LSN-2120310's activity against a wide range of menopausal symptoms

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...